View More Recent Stories
-
Envoy Medical Achieves Clinical Trial Milestone and is Optimistic About Expansion into Final Stage of Trial
-
Envoy Medical Reports on First Quarter 2025 Results
-
Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results
-
Hearing Device Coverage Clarification Act Reintroduced in House and Senate
-
Envoy Medical Secures $10 Million in Funding to Advance Pivotal Clinical Trial of Breakthrough Hearing Device
-
Envoy Medical to Participate in the 37th Annual ROTH Conference
-
First Two Participants Successfully Enrolled In Pivotal Clinical Study For Breakthrough Fully Implanted Cochlear Implant
-
Envoy Medical (COCH) Secures Additional Patent Protection for Its Growing Patent Portfolio
-
Envoy Medical Secures Additional Patent Protection for Its Growing Patent Portfolio
-
Envoy Medical Names Seven Investigational Sites for Participation in Its Pivotal Clinical Study
-
Envoy Medical (COCH) Receives Additional Patent Protection for its Innovative Approach to Hearing Loss
-
Envoy Medical (COCH) PT Lowered to $6 at Brookline Capital Markets
-
Envoy Medical (COCH): AMA Approves Groundbreaking New CPT Codes for Totally Implantable Active Middle Ear Hearing Implants Opening New Opportunities for Envoy Medical’s Esteem Device
-
Envoy Medical (COCH) Files $75M Mixed Shelf
-
Envoy Medical (COCH) PT Raised to $8.75 at Ascendiant Capital
-
Ascendiant Capital Starts Envoy Medical (COCH) at Buy
